Liver growth prediction in ALPPS - A multicenter analysis from the international ALPPS registry.
ALPPS
anthropometrics
liver cancer
liver regeneration
rapid hypertrophy
Journal
Liver international : official journal of the International Association for the Study of the Liver
ISSN: 1478-3231
Titre abrégé: Liver Int
Pays: United States
ID NLM: 101160857
Informations de publication
Date de publication:
12 2022
12 2022
Historique:
revised:
25
03
2022
received:
28
09
2021
accepted:
30
04
2022
pubmed:
10
5
2022
medline:
25
11
2022
entrez:
9
5
2022
Statut:
ppublish
Résumé
While ALPPS triggers a fast liver hypertrophy, it is still unclear which factors matter most to achieve accelerated hypertrophy within a short period of time. The aim of the study was to identify patient-intrinsic factors related to the growth of the future liver remnant (FLR). This cohort study is composed of data derived from the International ALPPS Registry from November 2011 and October 2018. We analyse the influence of demographic, tumour type and perioperative data on the growth of the FLR. The volume of the FLR was calculated in millilitre and percentage using computed-tomography (CT) scans before and after stage 1, both according to Vauthey formula. A total of 734 patients were included from 99 centres. The median sFLR at stage 1 and stage 2 was 0.23 (IQR, 0.18-0.28) and 0.39 (IQR: 0.31-0.46), respectively. The variables associated with a lower increase from sFLR1 to sFLR2 were age˃68 years (p = .02), height ˃1.76 m (p ˂ .01), weight ˃83 kg (p ˂ .01), BMI˃28 (p ˂ .01), male gender (p ˂ .01), antihypertensive therapy (p ˂ .01), operation time ˃370 minutes (p ˂ .01) and hospital stay˃14 days (p ˂ .01). The time required to reach sufficient volume for stage 2, male gender accounts 40.3% in group ˂7 days, compared with 50% of female, and female present 15.3% in group ˃14 days compared with 20.6% of male. Height, weight, FLR size and gender could be the variables that most constantly influence both daily growths, the interstage increase and the standardized FLR before the second stage.
Sections du résumé
BACKGROUND
While ALPPS triggers a fast liver hypertrophy, it is still unclear which factors matter most to achieve accelerated hypertrophy within a short period of time. The aim of the study was to identify patient-intrinsic factors related to the growth of the future liver remnant (FLR).
METHODS
This cohort study is composed of data derived from the International ALPPS Registry from November 2011 and October 2018. We analyse the influence of demographic, tumour type and perioperative data on the growth of the FLR. The volume of the FLR was calculated in millilitre and percentage using computed-tomography (CT) scans before and after stage 1, both according to Vauthey formula.
RESULTS
A total of 734 patients were included from 99 centres. The median sFLR at stage 1 and stage 2 was 0.23 (IQR, 0.18-0.28) and 0.39 (IQR: 0.31-0.46), respectively. The variables associated with a lower increase from sFLR1 to sFLR2 were age˃68 years (p = .02), height ˃1.76 m (p ˂ .01), weight ˃83 kg (p ˂ .01), BMI˃28 (p ˂ .01), male gender (p ˂ .01), antihypertensive therapy (p ˂ .01), operation time ˃370 minutes (p ˂ .01) and hospital stay˃14 days (p ˂ .01). The time required to reach sufficient volume for stage 2, male gender accounts 40.3% in group ˂7 days, compared with 50% of female, and female present 15.3% in group ˃14 days compared with 20.6% of male.
CONCLUSIONS
Height, weight, FLR size and gender could be the variables that most constantly influence both daily growths, the interstage increase and the standardized FLR before the second stage.
Identifiants
pubmed: 35533020
doi: 10.1111/liv.15287
pmc: PMC9796398
doi:
Types de publication
Multicenter Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2815-2829Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2022 The Authors. Liver International published by John Wiley & Sons Ltd.
Références
Ann Surg. 2021 Nov 1;274(5):874-880
pubmed: 34334642
J Am Coll Surg. 2013 Jul;217(1):126-33; discussion 133-4
pubmed: 23632095
HPB (Oxford). 2019 May;21(5):557-565
pubmed: 30314713
Front Surg. 2014 Apr 21;1:10
pubmed: 25593935
Liver Int. 2022 Dec;42(12):2815-2829
pubmed: 35533020
Ann Surg. 2021 Jan 1;273(1):e22-e24
pubmed: 32740247
Ann Surg. 2018 May;267(5):833-840
pubmed: 28902669
HPB (Oxford). 2020 Oct;22(10):1420-1428
pubmed: 32057681
Ann Surg. 2017 Nov;266(5):779-786
pubmed: 28806301
HPB (Oxford). 2018 May;20(5):462-469
pubmed: 29287736
Surgery. 2015 Apr;157(4):690-8
pubmed: 25704417
HPB (Oxford). 2019 Jul;21(7):898-905
pubmed: 30611560
Surgery. 2016 Jul;160(1):81-91
pubmed: 27059638
Ann Surg. 2012 Mar;255(3):415-7
pubmed: 22330039
J Gastrointest Surg. 2008 Feb;12(2):297-303
pubmed: 18060468
World J Surg. 2009 Apr;33(4):797-803
pubmed: 19172348
Eur J Clin Nutr. 1991 Dec;45 Suppl 3:31-42
pubmed: 1809567
Surg Oncol Clin N Am. 2002 Oct;11(4):955-68
pubmed: 12607582
Innov Surg Sci. 2017 Mar 24;2(1):1-8
pubmed: 31579727
Ann Surg. 2015 Nov;262(5):780-5; discussion 785-6
pubmed: 26583666
J Cell Physiol. 2007 Nov;213(2):286-300
pubmed: 17559071
Oncotarget. 2018 Jun 15;9(46):28267-28280
pubmed: 29963276
Ann Surg. 2019 Jan;269(1):114-119
pubmed: 29727331
Arq Gastroenterol. 2003 Jan-Mar;40(1):40-4
pubmed: 14534664
Br J Surg. 2013 Feb;100(3):388-94
pubmed: 23124776
HPB (Oxford). 2016 Aug;18(8):691-6
pubmed: 27485064
HPB (Oxford). 2009 Sep;11(6):510-5
pubmed: 19816616
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Ann Surg. 2014 Nov;260(5):839-46; discussion 846-7
pubmed: 25379855
Br J Surg. 2016 Oct;103(11):1521-9
pubmed: 27517369
Ann Transl Med. 2019 Nov;7(22):691
pubmed: 31930092
Ann Surg. 2012 Mar;255(3):405-14
pubmed: 22330038
Oncologist. 2008 Jan;13(1):51-64
pubmed: 18245012
HPB (Oxford). 2021 Jul;23(7):1000-1007
pubmed: 33191106
World J Surg. 2014 Jun;38(6):1510-9
pubmed: 24748319
BMC Public Health. 2019 Aug 5;19(1):1045
pubmed: 31382936
Surgery. 2017 May;161(5):1255-1265
pubmed: 28081953
Ann Surg. 2004 Dec;240(6):1037-49; discussion 1049-51
pubmed: 15570209
World J Surg. 2019 Sep;43(9):2281-2289
pubmed: 31119359
Ann Transl Med. 2020 Apr;8(7):436
pubmed: 32395480
Hepatobiliary Surg Nutr. 2014 Oct;3(5):238-46
pubmed: 25392835
Liver Transpl. 2002 Mar;8(3):233-40
pubmed: 11910568
J Gastrointest Surg. 2013 Apr;17(4):814-21
pubmed: 23188224
Ann Surg. 2021 Mar 1;273(3):442-448
pubmed: 32049675
Updates Surg. 2017 Sep;69(3):411-419
pubmed: 28795384
Ann Surg. 2020 Nov;272(5):793-800
pubmed: 32833765
J Surg Res. 2014 May 15;188(2):489-95
pubmed: 24569034
Saudi J Gastroenterol. 2016 Nov;22(6):428-434
pubmed: 27976638